Well stated Canes. People have to realize that it is rare for a drug to be successful in all 3 phases of clinical trials and get approval from the FDA. For me, worrying about all kinds of other indications (some of which like AD which is a bear) seems a waste when we have a drug that produced fabulous results in a phase III trial and received approval for an indication that is #1 or #2 killer and a drug that has achieved results in CVD that have not been seen in over 30 years since statins. There should be no reason that the CVD indication for V should not reward all Amarinites very handsomely.
I want to add that I share your sentiment about adding Monday morning on any drop. 2 problems for me to think about. First I think I have plenty of shares already, but secondly what am I going to dump to divert to AMRN????
News 
Market Data 
Discover 
